Pharmaceutical Companies

The partnership centers on incorporating Diagnoly’s Fetoly platform into GE HealthCare’s established Voluson women’s health ultrasound systems, marking a significant advancement in prenatal diagnostic technology.

The partnership merges Fujitsu Japan’s deep knowledge of the medical field and cutting-edge technologies, including artificial intelligence, with JMDC’s sophisticated prediction models derived from insurance user data.

Once fully operational, the manufacturing plant is expected to create direct employment opportunities for more than 500 people.

Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.

Once the transaction successfully closes, the combined company plans to operate under the PrimeGen US name or through a successor entity.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.

The trial will enroll up to 105 Japanese men across 11 sites throughout the country, with the collected data intended to support a future marketing authorization submission for TLX591-Px in Japan.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.